4 minute read
Journals News
New DMD Editorial Board Members
The Publications Committee recently approved the following new Drug Metabolism and Disposition Editorial Board members:
Advertisement
Dr. Shelby Anderson, AbbVie, North Chicago, IL
Dr. Klarissa D. Jackson, University of North Carolina, Chapel Hill, NC
Diane Ramsden, AstraZeneca Dr. Sam Arnold, University of Washington, Seattle, WA
Dr. Miki Nakajima, Kanazawa University, Kanazawa, Japan Dr. Guang-Bo Ge, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Dr. Luc Rogée, Eli Lilly & Co., Indianapolis, IN Dr. Jingkai Gu, Jilin University, Changchun, China
Dr. Dan Scotcher, University of Manchester, United Kingdom
Dr. Baojian Wu, Guangzhou University of Chinese Medicine, Guangzhou, China The Publications Committee thanks them and all ASPET editorial board members for their service and dedication to the Society’s journals.
The expression of drug-metabolizing enzymes when responding to stimulus signals is tightly regulated by a variety of transcription factors, including the nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR). These receptors are xenobiotic sensors that respond to environmental stimuli. The quest to understand the molecular mechanisms by which PXR and CAR control the expression of drug-metabolizing enzymes, including cytochrome P450s, has been one of the driving forces that established the current foundation of knowledge on the regulation of drug metabolism and disposition.
The special section on Drug Metabolism and Regulation found in Drug Metabolism and Disposition July 2022 (50/7) issue addresses the fundamental knowledge by the 2016 Bernard B. Brodie Award recipient Dr. Masahiko Negishi’s former mentor and trainees.
All content in the special section is freely accessible through February 2023.
Pharmacokinetics and ADME properties of therapeutic biologics, including molecular weight, substitutions of charged amino acids, FcRn interaction, targetmediated drug disposition (TMDD), and chemical modifications are important attributes for the safety and efficacy of these new drug modalities. The increasing complexity of therapeutic biologics demands more mechanistic ADME studies for many unsolved fundamental questions. The current DMD special section on Pharmacokinetics and ADME of Biological Therapeutics features eight review or research articles covering a wide range of topics, including industry perspectives, a white paper from the working group of The International Consortium for Innovation and Quality in Pharmaceutical Development, model-informed drug development of therapeutic biologics, the fate of the PEGylated copolymers, mechanistic investigation of renal elimination, and ADME characteristics and adverse drug reactions of antisense oligonucleotide drugs. These articles fully acknowledged the current knowledge gaps and described various technologies and the best practices that may expedite the evaluation of new therapeutic biologics using more efficient ADME studies and mathematical and mechanistic PK models.
All content in the special section on Pharmacokinetics and ADME of Biological Therapeutics is freely accessible through January 2023.
New Special Section Published in the Journal Drug Metabolism and Disposition Focuses on Unravelling the Functional Role of Orphan Transporters
The September 2022 issue of the ASPET journal
Drug Disposition and Metabolism, features a special section titled “New Era of Transporter Science: Unravelling the Functional Role of Orphan Transporters.” Dr. Kathleen M. Giacomini, a worldrenowned leader in membrane transporter biology, pharmacogenomics, and regulatory sciences, led efforts to prepare the six review articles. Dr. Giacomini, from the University of California, San Francisco, and her formal trainees outlined the recent advancement of de-orphaning research on solute carrier (SLC) transporters, their gene regulation, and their impact on drug disposition.
Membrane transporters play a major role in human physiology and in drug disposition and response. However, substrates and/or functions of many members in the SLC superfamily are still not known. Therefore, de-orphaning these SLC proteins becomes a matter of great importance in understanding the impact of genetic variants in these transporters on disease development and drug responses, and the functional consequences of their gene regulation.
The review articles highlight cutting-edge research on emerging roles of the human SLC 22 family, the regulatory sciences of studying transporter interactions, the role and application of transporters in disposition, tumor targeting and tissue toxicity of nuclear medicinal diagnostic reagents lobenguane and mIBG. In addition, the special section includes comprehensive reviews on SLC1 and SLC7 transporters in inflammation and immune responses, the epigenetic and nuclear receptor-mediated transcriptional regulation, and the impact of inflammation and infection on transporters in the placenta.
All content in the special section can be found in the September 2022 (50/9) issue of Drug Metabolism and is freely accessible through March 2023.
Highlighted Trainee Authors
Congratulations to the latest Highlighted Trainee Authors selected for Drug Metabolism and Disposition, The Journal of Pharmacology and Experimental Therapeutics, and Molecular Pharmacology:
Drug Metabolism and Disposition
■ Aditya Kumar (Univ. of
Washington) – June ■ Robert Betterton (Univ. of
Arizona) – July
JPET
■ Pasquale Mone (Campania
Univ.) – June ■ Edna Santos (Virginia Commonwealth Univ.) – July ■ Lloyd Wei Tat Tang (National Univ. of Singapore) – August Aditya Kumar Robert Betterton
Pasquale Mone Edna Santos Lloyd Wei Tat Tang
Molecular Pharmacology
■ Dr. Sharan Srinivasan (Univ. of Michigan) – July ■ Lei Zhang (Texas A&M
Univ.) – August
A brief description of their areas of research, current projects, the anticipated impact of their work, and what they enjoy when not in the lab is online at https://bit.ly/2yX1YeH. We congratulate all of them for being selected.
Sharan Srinivasan Lei Zhang
